■在一些随机对照试验(RCT)中,中药肚脐应用(CMBBA)已用于治疗儿童腹泻(CD),但其有效性和组合策略仍有待澄清。因此,我们旨在评估有效性,安全,以及CMBBA治疗CD的优化组合策略。
■直到2023年1月,我们在六个数据库中搜索了符合我们纳入标准的研究,包括PubMed,Cochrane图书馆,中国SinoMed,CNKI,VIP,还有万方。使用I2统计学对异质性进行量化。使用Cochrane风险偏差工具2.0进行方法学评估。采用网络Meta分析的可信度在线软件对证据分级进行评估。使用最小语境框架为网络荟萃分析提供了全面的结论。本研究方案在PROSPERO注册。
■我们分析了33项RCT的数据,其中包括4,490名腹泻儿童。就临床效果而言,根据最小情境化框架,CMBBA加蒙脱石粉加抗感染药可能是腹泻和并发感染儿童最有效的治疗选择。单独使用CMBBA或CMBBA与现代医学联合使用有利于减少腹泻消失的时间(MD=-1.33天,95%CI:-1.59至-1.08,Z=-10.103,p<0.001)与现代医学相比,差异有统计学意义。CMBBA的联合使用可以将脱水恢复时间平均缩短0.74天(MD=-0.74天,95%CI:-1.10至-0.37,Z=-3.931.103,p<0.001)。虽然一些研究报道了使用CMBBA后的轻度过敏反应和轻度腹痛,这些症状可以在相对较短的时间内治愈。
■CMBBA的组合,蒙脱石粉,和抗感染药物可以为腹泻和并发感染的儿童提供更好的临床疗效。要治疗CD,CMBBA可以有效和安全地使用。然而,由于临床试验数量有限且研究质量较低,因此必须谨慎解释研究结果.此外,治疗方案的选择也应根据每个患者的具体情况而定。
■https://www.crd.约克。AC.英国/普华永道/,标识符:CRD42022350694。
UNASSIGNED: Chinese medicine belly button application (CMBBA) has been used to treat childhood diarrhea (CD) in several randomized controlled trials (RCTs), but its effectiveness and combination strategy still need to be clarified. Therefore, we aimed to evaluate the effectiveness, safety, and the optimal combination strategy of CMBBA in treating CD.
UNASSIGNED: Up until January 2023, we searched for studies that met our inclusion criteria in six databases, including PubMed, the Cochrane Library, Chinese SinoMed, CNKI, VIP, and Wanfang. Heterogeneity was quantified using I2 statistics. A methodological evaluation was performed using the Cochrane Risk Bias Tool 2.0. The Confidence in Network Meta-Analysis online software was employed to evaluate evidence grading. A minimally contextualized framework was used to provide a comprehensive conclusion for the network meta-analysis. This study protocol was registered with PROSPERO.
UNASSIGNED: We analyzed data from 33 RCTs that included 4,490 children with diarrhea. In terms of clinical effectiveness, CMBBA plus montmorillonite powder plus anti-infectives may be the most effective treatment option for children with diarrhea and concurrent infection according to a minimally contextualized framework. Either exclusive use of CMBBA or CMBBA in combination with modern medicine was beneficial in reducing the time to diarrhea disappearance (MD = -1.33 days, 95% CI: -1.59 to -1.08, Z = -10.103, p < 0.001) compared to modern medicine exclusively, and the difference was statistically significant. The combined usage of CMBBA could shorten the recovery time of dehydration by an average of 0.74 days (MD = -0.74 days, 95% CI: -1.10 to -0.37, Z = -3.931.103, p < 0.001). While some studies have reported mild allergic reactions and mild abdominal pain after CMBBA use, these symptoms can be cured in a relatively short period of time.
UNASSIGNED: The combination of CMBBA, montmorillonite powder, and anti-infectives may provide superior clinical effectiveness for children with diarrhea and concurrent infection. To treat CD, CMBBA can be used effectively and safely. However, the findings must be interpreted with cautiously due to the limited number of clinical trials and the low quality of the studies. In addition, the choice of treatment plan should also be based on the specific conditions of each patient.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier: CRD42022380694.